DURECT
  • ABOUT
    • ABOUT DURECT
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • CORPORATE GOVERNANCE
      • BOARD COMMITTEE CHARTERS
      • CODE OF ETHICS
      • WHISTLEBLOWER POLICY
      • CORPORATE GOVERNANCE GUIDELINES
  • PRODUCTS
    • ALZET® Osmotic Pumps
    • LACTEL® Absorbable Polymers
  • PIPELINE
    • OVERVIEW
    • IN DEVELOPMENT
      • DUR-928
      • POSIMIR® (bupivacaine extended-release solution)
      • ORADUR® -Methylphenidate ER
      • SUSTAINED-RELEASE Ophthalmology Product
  • SCIENCE & TECHNOLOGIES
    • EPIGENETIC REGULATORS
    • LONG-ACTING INJECTABLES
      • SABER® PLATFORM
      • CLOUD® PLATFORM
    • ORADUR® ABUSE-DETERRENT TECHNOLOGY
    • TRANSDUR® TRANSDERMAL TECHNOLOGY
    • PATENTS
    • PUBLICATIONS
      • POSIMIR® (SABER® -Bupivacaine)
      • EPIGENETIC REGULATOR PROGRAM
      • SABER® & CLOUD® Injectable Depot Systems
  • INVESTORS
    • OVERVIEW
    • STOCK INFORMATION
    • NEWS RELEASES
    • COLLABORATIONS
    • EARNINGS ESTIMATE
    • ANALYST COVERAGE
    • CORPORATE PRESENTATION
    • FINANCIAL REPORTS
    • SEC FILINGS
    • EVENT CALENDAR
    • FAQs
    • EMAIL ALERTS
    • INFORMATION REQUEST
  • NEWS
    • NEWS RELEASES
    • MEDIA KIT

INVESTORS

  • Overview
  • Corporate Factsheet
  • Stock Information
  • News Releases
  • Collaborations
  • Earnings Estimate
  • Analyst Coverage
  • Corporate Presentation
  • Financial Reports
  • SEC Filings
  • Event Calendar
  • FAQs
  • E-mail Alerts
  • Information Request

Stock Chart

Stock QuoteStock ChartHistorical Price LookupInvestment Calculator
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources

© 2000- DURECT Corporation

BUSINESS DEVELOPMENT | CAREERS | CONTACT | LEGAL NOTICE | PRIVACY POLICY